Transcripta Bio

Transcripta Bio is an AI-driven drug discovery company founded in 2018 that has developed a first-of-its-kind integrated platform combining high-resolution transcriptomic screening with frontier AI models. The company systematically screens diverse small molecules to build a perturbation atlas, which powers its 'Conductor AI' to predict gene responses and design novel drug candidates for synthesis and validation in its wet lab. This closed-loop system is designed to identify and advance therapeutic programs with unprecedented speed and scale, a capability recognized by its inclusion in the TIME100 Most Influential Companies of 2024. Transcripta Bio operates as a private, likely pre-revenue company advancing a pipeline from discovery through clinical stages.

Integrated 'lab-in-the-loop' platform combining high-throughput whole-transcriptome screening of molecules in human cell lines with frontier AI models (Conductor AI) that predict gene responses and design novel drug candidates for synthesis and validation.

Transcripta Bio operates in the highly competitive AI/ML-driven drug discovery sector, competing with well-funded players like Recursion Pharmaceuticals, Exscientia, Insilico Medicine, and Relay Therapeutics. Its key differentiator is the deep integration of its own large-scale, purpose-built transcriptomic screening data to train its AI models, creating a proprietary data moat. However, it must continually advance its technology and demonstrate superior clinical outcomes to maintain a competitive edge.